ArticleClinical hemorheology and microcirculation2025
Utilizing multimodal ultrasonography in conjunction with serum Ki-67 and HER2 tests for breast cancer detection and prognosis.
Article in Clinical hemorheology and microcirculation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction · 2025-11-23Compromised Peer Review · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Third Party Involvement · Investigation by Journal/Publisher ·
- Retracted
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo examine the diagnostic and prognostic value of multimodal ultrasound and serum human epidermal growth factor receptor 2 (HER2) and Ki-67 antigen (Ki-67) testing for breast cancer.MethodsWe enrolled 65 patients with breast cancer admitted to the Tianjin Fourth Centre Hospital between March 2018 and March 2019 as the study group, while the control group consisted of 65 patients with benign breast nodules admitted during the same time period. All cases underwent ultrasound elastography (UE), contrast-enhanced ultrasonography (CEUS), serum examination, and Ki-67 and HER2 testing to determine the differences in multimodal ultrasound parameters and biomarkers, respectively, between the two groups and their relationship to the pathological features of breast cancer; ROC curves were generated to determine the accuracy of the combined examination in predicting breast cancer prognosis.ResultsThe study group had significantly higher UE score and CEUS-PI, significantly lower time to peak (TTP) and mean transit time (MTT) levels than the control group (
Indexed as
Identifiers
39973433What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.